Completed PHASE2/PHASE3 INTERVENTIONAL NCT00219583

Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation

A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation

Sponsor: Pfizer

Conditions Ejaculation

Interventions UK-390,957

Updated 6 times since 2017 Last updated: Nov 5, 2012 Started: Aug 31, 2004 Primary completion: Jun 30, 2005 Completion: Jun 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Ejaculation, this trial is completed. The trial is conducted by Pfizer and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Balcali, Turkey (Türkiye) , Balçova, Turkey (Türkiye) , Barcelona, Spain , Beersheba, Israel , Bialystok, Poland , BodÃ¸, Norway , Bondi Junction, Australia , Brno, Czechia , Edmonton, Canada and 39 more locations